Back to search
Hormone Receptor Positive Malignant Neoplasm of Breast
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hormone Receptor Positive Malignant Neoplasm of Breast trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hormone Receptor Positive Malignant Neoplasm of Breast trials you may qualify forThis phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER…
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which ty…
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Ef…
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determi…
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy o…
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic brea…
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standa…
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal stu…